 |
Prospector
Profile
2-8-004
|
| |
| Xpention Genetics, Inc. |
NAICS |
541710 |
| 10965 Elizabeth Drive
Conifer, CO 80433 |
Description |
Biotechnology |
| (303) 908-4900 |
Employees |
1 |
| http://www.xpention.com |
Revenue |
(mil) |
0.0000 |
| |
Income |
(mil) |
-0.2050 |
| |
Assets |
(mil) |
0.0240 |
| |
Liability |
(mil) |
0.4958 |
| |
(for the year ended 2007-05-31) |
| |
|
Category:
Loss/Deficit
|
| |
|
Event:
Xpention Genetics, Inc., had a net loss of $161,176 for the three months ended November 30, 2007, much higher than the $44,222 net loss reported during the three months ended November 30, 2006. For the six months ended November 30, 2007, the Company had a net loss of $235,358, much higher than the $98,909 net loss incurred during the six months ended November 30, 2006. The Company's balance sheet at November 30, 2007, showed an accumulated deficit of $1,574,033 and stockholders' deficit of $592,933. It also has strained liquidity with $9,746 in total current assets available to pay $602,679 total current liabilities.
|
| |
|
Intellectual Property:
The Company's wholly owned subsidiary, Xpention, Inc., has entered into a Patent and Technology License Agreement with the University of Texas M.D. Anderson Cancer Center. The Patent and Technology License Agreement grants Xpention the exclusive right to patented technology for the detection of cancer based on a tumor marker known as p65 which has been demonstrated to have elevated levels in the blood of canine and human cancer conditions. [SEC Filing 10-KSB 09-10-07]
|
| |
|
Description:
Xpention Genetics, Inc., develops immunological and molecular tests for cancer detection in animals and humans.
|
| |
|
Officers:
David Kittrell (Pres., CEO & CFO)
|
| |
|
Auditor:
Stark Winter Schenkein & Co. LLP
|
| |
|
Securities:
Common Stock-Symbol XPNG.OB; OTC BB; 59,975,833 common shares outstanding as of January 17, 2008.
|
| |
| |
| |
| return to main page |
|
|
